الفهرس 
Introduction
Hepatocellular carcinomaOnly 14 pages are availabe for public view
 |  | from | 168 |  |  |
| | | from | 168 | | |
Abstract
Introduction Primary liver cancer is the fifth most common cancer worldwideand the second leading cause of cancer related mortality. (XRCC1) is one of the most essential molecules in base excision repair. It has been reported that XRCC1 gene is an essential gene affecting HCC susceptibility.Aim of work The objective of this study was to investigate association betweenXRCC1 genevariants and susceptibility for HCC related to chronichepatitis C infection in Egyptian population and to find a possible relation to insulin resistance state. Patients and methods.This study was carried out on 140 patients and 70 healthy volunteer controls recruited from out and inpatient clinic of Tropical medicine department, Mansoura University, Dakahlya, Egypt between June 2014 and May 2015, divided into three groups 1-HCV related hepatocellular carcinoma group (70 patients):subclassified into a) IR subgroupb) Non-IR subgroup.2-HCV related liver cirrhosis group without hepatocellular carcinoma(70 patients)subclassified intoa) IR subgroupb) Non-IR subgroup.3-Control group (70 healthy subjects).Results and discussion.1- T-allele of c.1254C>T and C-allele of c.1517G>C genetic variants may increase the susceptibility of HCC.2-T-allele of c.1254C>T and C-allele of c.1517G>C genetic variants may be associated with increased risk of IR development in HCV infected patients. 3- T allele of c.1254C>T was significantly higher in IR-HCC groupthan in IR-cirrhotic, so HCV infected patients with IR and having T allele may be more liable to develop HCC.Summary & conclusions.1-Genetic analysis studies should be continued to detect a reliable,sensitive and specific genetic marker to define high risk group forHCC and XRCC1 may be one of them in the future .2-HCV related IR assessment by HOMA-IR and treatment of IR if present is recommended in patients with CHC as it this has several benefits (a) Improvement of the response to antiviral therapy (b) reduce the rate of progression to cirrhosis (c) reduce the risk of development of HCC.